Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2018 16:00 ET | Source: Principia Biopharma Inc.

Principia Biopharma Issues Statement About the Passing of Board Member Lewis J. Shuster

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies...
November 29, 2018 16:01 ET | Source: Principia Biopharma Inc.

Principia Biopharma Reports Positive PRN1008 Phase 2 Top-Line Results and Initiates Phase 3 Pemphigus Program

- Achieved Phase 2 primary endpoint – over 50% of patients attained Control of Disease Activity within four weeks of starting PRN1008 - - Demonstrated sustained clinical efficacy at 12 weeks of...
November 08, 2018 08:00 ET | Source: Principia Biopharma Inc.

Principia Biopharma to Present at 27th Annual Credit Suisse Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies...
November 06, 2018 16:01 ET | Source: Principia Biopharma Inc.

Principia Biopharma Reports Third Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies...
October 24, 2018 08:00 ET | Source: Principia Biopharma Inc.

Principia Biopharma Appoints Dolca Thomas, M.D. as Chief Medical Officer

- Succession designed to lead Principia through next phase of growth as a clinical-stage company - SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq:...
October 19, 2018 08:00 ET | Source: Principia Biopharma Inc.

Principia Biopharma Announces PRN1008 Receives Orphan-Drug Designation from FDA for Treatment of Immune Thrombocytopenic Purpura

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies...
October 16, 2018 08:00 ET | Source: Principia Biopharma Inc.

Principia Achieves $10 Million in Additional Milestones Related to Development of PRN2246/SAR442168

-- Additional milestones achieved under the Sanofi collaboration which is focused on treating diseases of the central nervous system -- SOUTH SAN FRANCISCO, Calif., Oct. 16, 2018 (GLOBE NEWSWIRE)...
September 26, 2018 16:01 ET | Source: Principia Biopharma Inc.

Principia Biopharma to Present at 2018 Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral...
September 18, 2018 16:00 ET | Source: Principia Biopharma Inc.

Principia Biopharma Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Principia or the Company) (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing...
September 13, 2018 22:49 ET | Source: Principia Biopharma Inc.

Principia Biopharma Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Principia or the Company, Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing...